Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4607]

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

Cellular messengers improve cancer therapy

Cellular messengers improve cancer therapy

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

World's first clinical trial with CAR-T technology for patients with T-cell leukaemia subtype authorised

ASH 2022: Striving to improve treatment options for acute myeloid leukaemia

ASH 2022: Striving to improve treatment options for acute myeloid leukaemia

3D-patient tumour avatars: Maximising their potential for next-generation precision oncology

3D-patient tumour avatars: Maximising their potential for next-generation precision oncology

FDA grants approval to atezolizumab for alveolar soft part sarcoma

FDA grants approval to atezolizumab for alveolar soft part sarcoma

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non...

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

More from ecancer